To better understand the impact of Cic disruption on tumor growth in KP mice, we first determined the genes potentially controlled by CIC by ChIP sequencing (ChIP-seq) in KPCic cells vs. KP cells left untreated or treated with the selective MEK inhibitor trametinib for 24 h to efficiently block the MAPK pathway and maximize CIC DNA binding. Here, MAP2K7 is linked to neoplasm.